Prescription ·Strong evidence ·Reviewed May 2026
Lovastatin was the first commercially available statin and is a moderate-intensity agent derived from Aspergillus terreus fungus. It was the first drug to clearly demonstrate that lowering cholesterol reduces cardiovascular events.
The bottom line
Evidence rating strong. Most-documented uses: lowers ldl cholesterol by 20–40%, proven reduction in first major coronary events (afcaps/texcaps trial), reduces triglycerides modestly. 10 sources indexed (1991–2025), with 6 interaction records on file.
Core mechanism
Inactive lactone prodrug that is hydrolyzed in vivo to the active beta-hydroxyacid form. Inhibits HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis. Metabolized by CYP3A4. Reduces hepatic cholesterol synthesis, upregulates LDL receptors, and increases LDL clearance.
Immediate-release lovastatin should be taken with the evening meal to increase bioavailability by ~50%; avoid grapefruit juice1
Nutrients this medication can lower over time, and what to replace.
HMG-CoA reductase inhibition reduces mevalonate pathway flux, lowering endogenous CoQ10 synthesis alongside cholesterol synthesis.
Grapefruit juice inhibits intestinal CYP3A4 and can substantially increase lovastatin exposure, raising myopathy and rhabdomyolysis risk.
Recommendation: Avoid grapefruit and grapefruit juice while taking lovastatin unless your prescriber specifically says otherwise.
Lovastatin can lower CoQ10 production by blocking the mevalonate pathway. CoQ10 depletion is a plausible contributor to statin-associated myalgia, though supplementation benefits are inconsistent across trials. CoQ10 is generally used as supportive therapy rather than as a replacement for statin adjustment.
Recommendation: Consider CoQ10 100-200 mg/day if you have muscle symptoms on lovastatin and your clinician agrees it is reasonable. Seek medical advice promptly for severe weakness, dark urine, or rapidly worsening muscle pain.
Lovastatin can reduce endogenous CoQ10 synthesis, and ubiquinol is the reduced form of CoQ10 used in many supplements. Restoring CoQ10 status may help some people with statin-associated muscle symptoms, but the clinical response is not guaranteed. Ubiquinol should be viewed as adjunctive symptom support.
Recommendation: If muscle aches occur on lovastatin, consider ubiquinol 100-200 mg/day after discussing symptoms and other causes with your prescriber. Get urgent help for severe muscle pain, weakness, fever, or dark urine.
High-dose Vitamin B3 as niacin can add muscle, liver, and glucose-related adverse effects to statin therapy. Large statin-era niacin trials found no cardiovascular outcome benefit from adding high-dose niacin, while adverse events increased. Low-dose nutritional niacin is different from pharmacologic niacin doses.
Recommendation: Avoid high-dose niacin, especially 500 mg/day or more, with lovastatin unless it is specifically prescribed and monitored. If the combination is used, monitor liver enzymes, glucose control, and any new muscle pain or weakness.
St. John's Wort can induce CYP3A4 and P-glycoprotein, which may lower exposure to CYP3A4-metabolized statins. Human data show a major reduction in simvastatin exposure, and lovastatin shares substantial CYP3A4 first-pass metabolism. This can make cholesterol control less reliable.
Recommendation: Avoid St. John's Wort while taking lovastatin unless your prescriber has explicitly approved it. If you have already combined them, tell your clinician and consider checking lipids after stopping St. John's Wort because induction can persist for days to weeks.
Lovastatin is highly dependent on CYP3A4 metabolism, and berberine has human evidence of inhibiting CYP3A4 after repeated dosing. This creates a plausible risk of increased lovastatin exposure and muscle toxicity, especially with high lovastatin doses or additional CYP3A4 inhibitors. Human clinical outcome data for this exact combination are limited.
Recommendation: Avoid adding high-dose berberine to lovastatin unless your prescriber agrees and knows your full medication list. Report muscle pain, weakness, dark urine, or marked fatigue promptly.
Numbered references. Citations throughout the page link here.
McKinney WS, Schmitt LM, De Stefano LA et al.. Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X Syndrome. Journal of child and adolescent psychopharmacology. 2025
Lin CH, Chang CH, Tai CH et al.. A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2021
Payne JM, Barton B, Ullrich NJ et al.. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016
Azie NE, Brater DC, Becker PA et al.. The interaction of diltiazem with lovastatin and pravastatin. Clinical pharmacology and therapeutics. 1998
Richter WO, Jacob BG, Schwandt P. Interaction between fibre and lovastatin. Lancet (London, England). 1991
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack